LDS/Medical Tests/Breast Cancer Gene Expression Profile (MammaPrint, BluePrint®)

Breast Cancer Gene Expression Profile (MammaPrint, BluePrint®)

Breast cancer is the most commonly diagnosed cancer in U.S. women (~240,000 new cases/year). Among newly diagnosed breast cancer patients, many are considered to have a good prognosis depending on features such as lymph node involvement (lymph node-negative) and estrogen receptor status (estrogen receptor-positive). Within this group, however, a significant number of patients will have a disease recurrence within their lifetime.

Breast cancer is heterogeneous with different tumor subtypes that are histologically similar but respond differently to therapy. Identifying the biological mechanisms of breast cancer can help to predict the behavior of the tumor. Specific biological mechanisms can be identified through gene expression analysis of breast cancer-related genes including increases and decreases in the expression of specific genes responsible for protein expression. The pattern of gene expression is represented by a score of low, medium or intermediate, and high risk.

Using these known patterns of gene expression, a 70-gene expression prognostic signature (i.e., expression profile) was developed to estimate the likelihood of breast cancer recurrence including distant metastasis in node-negative (N-), ER-positive (ER+) breast cancer patients. The ability to better stratify patients by prognostic class may allow for informed patient management decisions. The results of this test should only be considered in conjunction with other clinical and prognostic parameters.

The MammaPrint® test analyzes the 70 most important genes associated with breast cancer recurrence. Results are typically available in 6 days or less, MammaPrint enables quicker, more informed decisions on pre- and post-operative treatment and can easily be integrated into diagnostic workups.

BluePrint is an 80-gene genomic subtyping test that classifies breast tumors by their underlying biology—Luminal, HER2-type, or Basal—helping guide more personalized treatment decisions. By going beyond traditional pathology, BluePrint reveals the true drivers of tumor growth, identifying aggressive tumors that may be misclassified to help guide the most appropriate therapy at diagnosis.

  • Breast Cancer Molecular Subtyping
  • Evaluate patient prognosis
  • Risk of recurrence
  • Potential information for adjuvant chemotherapy
Interpretation depends on the expression of gene studied. Some can be over-expressed and some suppressed. Each report will have an individualized interpretation depending on genes expressed, which then is linked with disease prognosis and management.

Negative for abnormal gene experession (Negative for gene expression array)

 

 

Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).

Immunohistochemistry (IHC).

Fluorescent in situ hybridization (FISH).

cDNA microarray (quantitative cDNA detection). 

Tumor: Formalin fixed, paraffin embedded tissue, fresh tissue, and frozen tissue (microdissection).

BRCA-1, BRCA-2, Hormone Receptor Status, Her2/neu by IHC and FISH, ER/PR by IHC, DNA ploidy, S-Phase fraction, CA 15-3, CA 27.29.
Approximately 2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login